CIK 0001662579 · Non-accelerated filer<br>Smaller reporting company
C4 Therapeutics, Inc.
Sign in to watch- Ticker
- CCCC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475617627
- Phone
- (617) 231-0700
- Business address
- 490 ARSENAL WAY, SUITE 120, WATERTOWN, MA, 02472
- 4 Option exercise Director acquired 2,137 shares (option exercise)
- 8-K/A Event Exhibits
- 4 Grant or award Director acquired 428 shares (grant or award)
- 4 Grant or award Director acquired 199 shares (grant or award)
- 4 Grant or award Director acquired 657 shares (grant or award)
- 4 Grant or award Director acquired 318 shares (grant or award)
- 4 Grant or award Director acquired 278 shares (grant or award)
- 8-K Event Results of operations · Regulation FD disclosure
- 4 Open-market sale Chief Medical Officer sold 15,000 shares at an average $31.66 ($474,968)
- 4 Option exercise Chief Medical Officer acquired 5,000 shares (option exercise)
- 4 Open-market sale Director sold 755 shares at $30.25 ($22,839)
- 4 Option exercise Chief Scientific Officer acquired 20,562 shares (option exercise)
- 8-K Event Material agreement · New debt or obligation
- 4 Open-market sale Director sold 755 shares at $40.11 ($30,283)
- S-3ASR Offering Registration Statement
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale Director sold 755 shares at $44.94 ($33,930)
- 4 Option exercise Chief Medical Officer acquired 10,000 shares (option exercise)
- 4 Grant or award Director acquired 300 shares (grant or award)
Page 21 of 28 · 549 filings